INVO Bioscience, Inc. (IVOB) [Rocket]

Overview

INVO Bioscience, Inc. (IVOB)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/05/2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
10/03/2023	8-K	Other Events  Interactive Data
10/02/2023	DEFA14A	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/29/2023	8-K	Other Events, Financial Statements and Exhibits  Interactive Data
09/28/2023	DEFA14A	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/21/2023	PRE 14A	Form PRE 14A - Other preliminary proxy statements:
08/14/2023	8-K	Quarterly results

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	4.2	1.0	1.5	0.5	0.3	0.1	0.0	0.0
Revenue growth	301.1%	-29.9%	199.4%	75.2%	454.3%	335.5%	-29.5%	-38.7%
Cost of goods sold	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
Gross profit	4.0	0.9	1.3	0.4	0.2	0.0	0.0	0.0
Gross margin	96.5%	91.4%	90.6%	81.7%	81.6%	70.3%	33.2%	53.7%
Selling, general and administrative	9.0	6.1	3.1	3.0	0.9	2.1	0.6	1.7
Research and development	0.2	0.4
EBITA	-5.5	-5.5	-1.8	-2.6	-0.6	-2.1	-0.6	-1.7
EBITA margin	-133.2%	-531.5%	-120.8%	-532.8%	-227.0%	-4146.1%	-5090.9%	-10131.3%
Amortization of intangibles	0.0	0.0
EBIT	-5.5	-5.5	-1.8	-2.6	-0.6	-2.1	-0.6	-1.7
EBIT margin	-133.3%	-531.7%	-120.8%	-532.8%	-227.0%	-4146.1%	-5090.9%	-10131.3%
Pre-tax income	-6.7	-8.3	-2.2	-3.1	-0.7	-2.1	-5.0	-1.7
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate				0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-6.7	-8.3	-2.2	-3.1	-0.7	-2.1	-5.0	-1.7
Net margin	-161.1%	-800.2%	-146.4%	-622.2%	-248.9%	-4173.3%	-42426.6%	-10444.1%

Diluted EPS	($0.63)	($1.51)	($0.45)	($0.02)	$0.00	($0.02)	($0.04)	($0.02)
Shares outstanding (diluted)	10.6	5.5	4.9	147.3	141.3	139.2	128.6	112.7

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.